{"entity":{"id":"nct07509515","kind":"trial","name":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","aka":[],"tldr":"A phase 2 trial of iparomlimab and tuvonralimab in triple-negative breast cancer, run by Fudan University, not yet recruiting.","summary":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. is a phase 2, randomised interventional study registered as NCT07509515 by Fudan University, with a registry enrolment figure of 60 participants, started 2026-04-15 and due to reach its primary completion in 2027-09-30. Interventions recorded: QLC5513; QLC5513+QL1706. Conditions listed: Triple-negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: \"TNBC invasive breast cancer confirmed by histology (specific definition: ER \\<1% positive tumor cells by immunohistochemistry are defined as ER negative, PR \\<1% positive tumor cells are defined as PR negative, HER2 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negat\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07509515","url":"https://clinicaltrials.gov/study/NCT07509515"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":["iparomlimab-tuvonralimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07509515","phase":"2","setting":"An Open-label, Phase 2 Study of QLC5513 Alone or in Combination With Epalolimab Tovolimab (QL1706) in Previously Treated Advanced or Metastatic TNBC.","sponsor":"Fudan University","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07509515/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"drug":[{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}